Apoptosis in the lacrimal gland and conjunctiva of dry eye dogs

Advances in Experimental Medicine and Biology

Volumn 438, Issue , 1998, Pages 453-460

  Gao, Jianping ^a   Gelber Schwalb, Tammy A ^a   Addeo, John V ^a   Stern, Michael E ^a  

^a ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

ANIMAL EXPERIMENT; APOPTOSIS; AUTOIMMUNITY; CONFERENCE PAPER; CONJUNCTIVA; DOG; HARDER GLAND; IMMUNOSUPPRESSIVE TREATMENT; KERATOCONJUNCTIVITIS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SJOEGREN SYNDROME;

ANIMALIA; CANIS FAMILIARIS;

EID: 0031744713     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5359-5_63     Document Type: Conference Paper

References (40)

1. Pflugfelder SC, Wilhelmus KR, Osato MS, et al. The autoimmune nature of aqueous tear deficiency. Ophthalmology. 1986;93:1513-1517.
2. Fox RL. Epidemiology, pathogenesis, animal models, and treatment of Sjögren's syndrome. Curr Opin Rheumatol. 1994;6:501-508.
3. Sullivan DA, Wickham LA, Krenzer KL, et al. Aqueous tear deficiency in Sjögren's syndrome: possible causes and potential treatment. In: Pleyer U, Hartmann C, Sterry W, eds. Oculodermal Diseases: Immunology of Bullous Oculo-Miico-Cutaneous Disorders. Buren, The Netherlands: Aeolus Press, 1997:95-152.
4. Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol. 1980;86:251-306.
5. Duke RC, Ojaius DM, Young JD. Cell suicide in health and disease. Sci Am. I996;275:80-87.
6. Watanabe-Fukunaga R, Brannan CI, Copeland NG. Lymphoproliferation disorder in mice explained by defects in fas antigen that mediates apoptosis. Nature. 1992:356:314-317.
7. Wu AJ, Chen ZJ, Tsokos M, et al. Interferon-gamma induced cell death in a cultured human salivary gland cell line. J Cell Physiol. 1996;167:297-304.
8. Rose LM, Latchman DA, Isenberg DA. Bcl-2 and fas, molecules which influence apoptosis. A possible role in systemic lupus erythematosus. Autoimmmunity. 1994;17:271-278.
9. Gao J, Gelbert-Schwalb TA, Addeo JV, Stern MS. Apoptosis in the rabbit cornea after photorefractive keratectomy. Cornea. 1997;16:200-208.
10. Prigent P, Blanpied C, Aten J, Hirsch F. A safe and rapid method for analyzing apoptosis-induced fragmentation of DNA extracted from tissues or cultured cells. J Immunol Methods. 1993;160:139-140.
11. Fox RI, Pisa P, Pisa EK, Rang HI. Lymphoproliferative disease in SCID mice reconstituted with human Sjögren's syndrome lymphocytes. J Clin Lab Anal. 1993;7:46-56.
12. Haneji N, Hamano H, Yanagi K, Hayashi Y. A new animal model for primary Sjögren's syndrome in NFS/sId mice. J Immunol. 1994;153:2769-2777.
13. Johnson BC, Morton JI, Trune DR. Lacrimal and salivary gland inflammation in the C3H/Ipr autoimmune strain mouse: a potential mode for Sjögren's syndrome. Otolaryngol Head Neck Surg, 1992;106:394-399.
14. Sullivan DA. Androgen-induced suppression of autoimmune disease in lacrimal glands of mouse models of Sjögren's syndrome. Adv Exp Med Biol. 1994;350:683-690.
15. Kaswan RL. Keratoconjunctivis sicca: immunological evaluation of 62 canine cases. Am J Vet Res. 1985;46:376-383.
16. Kaswan RL, Salisbury MA, Ward DA. Spontaneoud canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: Treatment with cyclosporine eye drops. Arch Ophthalmol. 1989;107:1210-1216.
17. Kaswan RL. Characteristics of a canine model of KCS: effective treatment with topical cyclosporine. Adv Exp Med Biol. 1994;350:583-594.
18. Allansmith M. Immunology of the tears. Int Ophthalmol Clin. 1973;13:47-72.
19. Wieczorek R, Jacobiec FA, Sacks EH, Knowles DM. The immunoarchitecture of the normal human lacrimal gland. Ophthalmology. 1988;95:100-109.
20. Fine BS, Yanoff M. Ocular Histology. Harper & Row, 1979;308-309.
21. Azzarolo AM, Olsen E, Huang ZM, et al. Rapid onset of cell death in lacrimal glands after ovaritectomy. Invest Ophthalmol Vis Sci. 1996;37:S856.
22. Walker NI, Gobe GC. Cell death and cell proliferation during atrophy of the rat parotid gland induced by duct obstruction. J Pathol. 1987;153:333-344.
23. 2+ - dependent cleavage of DNA into kilobase pair fragments is responsible for the initial degradation of DNA in apoptosis. J Biol Chem. 1994;269:14857-14860.
24. Hale AJ, Smith CA, Sutherland LC, et al. Apoptosis: molecular regulation of cell death. Eur J Biochem. 1996:236:1-26.
25. Fox RL. In: Lieberman R, ed. Apoptosis, cancer and p53 tumour suppressor gene. Cancer Metastasis Rev. 1995;14:149-161.
26. Tilkin AF, Lubin R, Soussi T, et al. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol. 1995;25:1765-1769.
27. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p-53 independent mechanisms inhibitable by bcl-2. Cell. 1994;79:329-339.
28. Pritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA damaging agents. Oncogene. 1993;8:307-318.
29. Dong X, Hamilton KJ, Satoh M, et al. Initiation of autoimmunity to the p53 tumor suppressor protein by complexes of p53 and SV40 large T antigen. J Exp Med. 1994;179:1243-1252.
30. Starzl TE. New approaches in the use of Cyclosporine: with particular reference to the liver. Transplant Proc. 1988;20:356-360.
31. Gunn HC, Ryffel B. Successful treatment of autoimmunity in (NAB X NZW) F1 mice with cyclosporin and (Nva)-Cyclosporin. II. reduction of glomerulonephritis. Clin Exp Immunol. 1986;64:234-242.
32. Liu SH, Zhou D-H, Gottsch JD, et al. Treatment of experimental autoimmune dacryoadenitis with Cyclosporin A.. Clin Immunol Immunopathol. 1993;67:78-83.
33. Hess AD. Mechanisms of action of cyclosporine: Considerations for the treatment of autoimmune diseases. Clin Immunol Immunopathol. 1993;68:220-228.
34. Jabs DA, Lee B, Burek CL, et al. Cyclosporine therapy suppresses ocular and lacrimal gland diseases in MRL/MP-lpr/lpr Mice. Invest Ophthalmol Vis Sci. 1996;37:377-383.
35. Stern MS, Gelber TA, Gao J, et al. The effects of topical cyclosporine A (CsA) on dry eye dogs (KCS). ARVO Abstracts. Invest Ophthalmol Vis Sci. 1996;37:S1026.
36. Morgan RV, Abrams KL. Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs. JAm Vet Med Assoc. 1991;199:1043-1046.
37. Olivero DK, Davidson MG, English RV, et al. Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs. J Am Vet Med Assoc. 1991;199:1039-1042.
38. Zierhut M, Thiel HJ, Weidle EG, et al. Topical treatment of severe corneal ulcers with cyclosporine A. Graefes Arch Clin Exp Ophthalmol. 1989;227:30-35.
39. Liegner JT, Yee RW, Wild JH. Topical cyclosporine therapy for ulcerative keratitis associated with rheumatoid arthritis. Am J Ophthalmol. 1990;109:610-612.
40. Jones DT, Monroy D, Ji Z, et al. Sjögren's syndrome; cytokine and Epstein-Barr virus gene expression within the conjunctival epithelium. Invest Ophthalmol Vis Sci. 1994;35:3493-3503.